Fas counter-attack-the best form of tumor defense?

Nature Medicine

Volumn 5, Issue 3, 1999, Pages 267-268

  O'Connell, Joe ^a   Bennett, Michael W ^a   O'Sullivan, Gerald C ^b   Collins, J Kevin ^a   Shanahan, Fergus ^a  

^a University College Cork and INFANT Centre   (Ireland)

^b MERCY UNIVERSITY HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR ANTIGEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING AFFINITY; CANCER INHIBITION; CANCER PREVENTION; CANCER STAGING; GENE EXPRESSION; LIGAND BINDING; LYMPH NODE METASTASIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; SHORT SURVEY; TUMOR CELL CULTURE;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; FAS LIGAND PROTEIN; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASMS;

ANIMALIA;

EID: 0032978137     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/6477     Document Type: Short Survey

References (13)

1. O'Connell, J., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184, 1075-1082 (1996).
2. Cardi, G., Heaney, J.A., Schned, A.R. & Ernstoff, M.S. Expression of Fas (APO-1/CD95) in tumor-infiltrating and peripheral blood lymphocytes in patients with renal cell carcinoma. Cancer Res. 58, 2078-2080 (1998).
3. Daniel, P.T. et al. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J. Immunol. 159, 3808-3815 (1997).
4. Hahne, M. et al. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science 274, 1363-1366 (1996).
5. Bennett, M.W. and O'Connell, J. et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J. Immunol. 160, 5669-5675 (1998).
6. Khar, A., Varalakshmi, C., Pardhasaradhi, B.V.V., Mubarak Ali, A. & Kumari, A. L. Depletion of the natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing Fas ligand: a mechanism of immune evasion. Cell. Immunol. 189, 85-91 (1998).
7. Maeda, A., Aragane, Y. & Tezuka, T. Expression of CD95 ligand in metanocytic lesions as a diagnostic marker. Br. J. Dermatol. 139, 198-206 (1998).
8. Li, X.K. et al. Prolonged survival of rat liver allografts transfected with Fas ligand-expressing plasmid. Transplantation 66, 1416-1423 (1998).
9. Chen, J.-J., Sun, Y. & Nabel, G.J. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282, 1714-1717 (1998).
10. O'Connell, J. et al. Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 186, 240-246 (1998).
11. Tanaka, M., Itai, T., Adachi, M. & Nagata, S. Down-regulation of Fas ligand by shedding. Nature Med. 4, 31-36 (1998).
12. Griffith, T.S., Yu, X., Herndon, J.M., Green, D.R. & Ferguson, T.A. CD95-induced apoptosis of lymphocytes in an immune privileged site induces immunological tolerance. Immunity 5, 7-16 (1996).
13. O'Connell, J., Bennett, M.W., O'Sullivan, G.C., Collins, J.K. & Shanahan, F. The Fas counterattack: cancer as a site of immune privilege. Immunol. Today 20, 46-52 (1999).